Gregory B. Sephton, Ph.D.

Partner
O: (212) 484-9866 x122
[email protected]
 

Gregory B. Sephton

Gregory B. Sephton, Ph.D., has over 25 years of experience in all aspects of patent litigation and has played leading roles in litigating and trying patent cases for a number of technology leaders, including Emory University, AstraZeneca, Novartis, Sanofi and Warner Chilcott. Most recently, Mr. Sephton led Forward Pharma to a $1.25 billion settlement in its worldwide patent dispute with Biogen over rights to its Tecfidera® multiple sclerosis treatment.

His litigation experience spans diverse technologies involving medical devices, chemicals, pharmaceuticals and biologicals. Greg also advises clients on patent strategy, as well as ex parte and inter partes patent reexaminations. He has particular experience litigating billion dollar pharmaceutical patent cases under the Hatch-Waxman Act, including involving anti-viral drugs, insomnia drugs, drugs for Alzheimer’s disease, anti-fungal drugs, anti-bacterial drugs and treatments, and anti-ulcer drugs, as well as a wide array of drug formulation technologies. He also has significant experience in intellectual property counseling, due diligence and transactions.

Prior to joining Pierce Bainbridge, Mr. Sephton was a partner at Kramer Levin Naftalis & Frankel LLP. Before that, he spent over 20 years at the Chambers Band 1-ranked New York IP boutique, Fitzpatrick, Cella, Harper & Scinto, where he was also a partner. Mr. Sephton holds degrees from the University of Toronto (B.Sc. Hons), Brandeis University (Ph.D., biochemistry, under a Merck grant) and Suffolk University (J.D.).

IN THE NEWS

Read the latest about our state-of-the-art litigation law firm.

PRACTICE AREAS

NOTABLE REPRESENTATIONS

Warner Chilcott against Actavis, Heritage, Impax, Mylan and Sandoz on a patent covering Doryx® brand doxycycline hyalite tablets.

Sanofi-Aventis against Barr, Mutual, Synthon and Watson on a patent relating to formulations of zolpidem Ambien CR® (zolpidem), a sleeping aid.

Novartis against Barr, Watson and Dr. Reddy’s on patents concerning the Alzheimer’s drug Exelon® (rivastigmine).

KOS Pharmaceuticals against Bar on patents covering KOS’ Niaspan® anti-cholesterol drugs.

AstraZeneca in multi-district litigation involving the anti-ulcer drug, PRILOSEC® (omeprazole).

Bausch & Lomb in Bausch & Lomb v. Alcon and Bausch & Lomb v. Allergan (contact lens care products containing proteolytic enzymes and antimicrobial agents).

Emory University in Emory University v. Glaxo-Wellcome and Emory University v. BioChem Pharma and Glaxo-Wellcome (anti-AIDS and anti-hepatitis pharmaceuticals).

The Liposome Co. in The Regents of the University of Texas v. The Liposome Company involving anti-fungal pharmaceuticals.

Representation of Forward Pharma in a worldwide patent dispute with Biogen over rights to its Tecfidera® multiple sclerosis treatment, resulting in a settlement that included a $1.25 billion non-refundable payment to Forward Pharma.

Represented Merck in a bench trial in the District of Delaware against Xellia Pharmaceuticals, obtaining a judgment of infringement of a patent relating to caspofungin (Cancidas), a lifesaving anti fungal drug.

Representation of AstraZeneca in its Hatch-Waxman litigations relating to its anti-ulcer medication, Prilosec®, obtaining a judgment that caused the client’s stock price to increase more than 10%.

 
New York
20 West 23rd Street, Fifth Floor, New York, NY 10010

Top